RIBOMIC’s Umedaptanib Pegol Achieves Strong Growth Outcomes in Children with Achondroplasia: Phase 2 Data Support Advancement to Late-Stage Clinical Development RIBOMIC, Inc. (TOKYO: 4591), a Japan-based clinical-stage biotechnology company focused on aptamer therapeutics, announced highly encouraging results from its Phase…
DemeRx Secures $1.7 Million NIH Grant to Advance First-in-Class Neuroplastogen DMX-1001 for Alcohol Use Disorder DemeRx, Inc., a clinical-stage biopharmaceutical company committed to transforming addiction therapeutics through innovative neuroscience, announced that it has been awarded a $1.7 million Small Business…
KalVista Pharmaceuticals Highlights EKTERLY® (Sebetralstat) as a Transformative Oral On-Demand Therapy for Hereditary Angioedema in Europe KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage biotechnology company focused on developing innovative therapies for hereditary angioedema (HAE) and related disorders, today unveiled compelling…
Merck Reports Clinical Positive Phase 3 HYPERION Trial Results for WINREVAIR™ (sotatercept-csrk) in Newly Diagnosed Pulmonary Arterial Hypertension Patients Merck known as MSD outside the United States and Canada, today announced encouraging findings from the Phase 3 HYPERION trial evaluating…
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative therapies for life-threatening diseases, has announced the publication of Phase…
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05 phase 3 clinical trial have reinforced the potential of ENHERTU®…
Savara Presents New Phase 3 IMPALA-2 Data on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025 Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies for rare respiratory diseases, announced the presentation of new analyses…
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering patient-specific therapies for rare diseases, has announced the publication of…
BioAlberta Celebrates Industry Leaders with Annual Achievement Awards at Health and Life Sciences Showcase Each year, Global Biotech Week and Life Sciences Week serve as a reminder of the enormous progress being made in Alberta’s thriving life sciences ecosystem. These…
ScaleReady Awards G-Rex® Grants to Advance Cell and Gene Therapy Manufacturing Across California ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, announced a major step forward in its commitment to advancing cell and…
BOTOX® Cosmetic Unveils “The One & Only” Campaign: A Celebration of Authenticity, Self-Expression, and Patient Stories A New Chapter for an Iconic Brand BOTOX® Cosmetic (onabotulinumtoxinA), one of the most recognizable names in aesthetics, has launched a new national campaign…
Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader in RNA interference (RNAi) therapeutics, has announced the commencement of…